Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.34 |
| ▸ | HPGD | P15428 | 4/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | GRK6 | P43250 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19374112 | 0.77 | TDP1 (0.34) | CYP1A2MAOAAHRALDH1A1HSD17B10 | |
| SCHEMBL19374115 | 0.77 | GPR3 (0.35) | CYP1A2MAOAALDH1A1HSD17B10HPGD | |
| SCHEMBL31280686 | 0.76 | ALDH1A1 (0.42) | CYP1A2ERBB2FYNMAOAACHE | |
| SCHEMBL4851809 | 0.71 | CYP1A2 (0.45) | CYP1A2ERBB2FYNMAOAACHE | |
| SCHEMBL26028 | 0.71 | CYP1A2 (0.47) | CYP1A2ERBB2FYNMAOAACHE | |
| SCHEMBL29562021 | 0.71 | CYP1A2 (0.47) | CYP1A2ERBB2FYNMAOAACHE | |
| SCHEMBL30024309 | 0.70 | GRK6 (0.37) | CYP1A2ALDH1A1HSD17B10HPGDL3MBTL1 | |
| Triphenylene SCHEMBL22493025 | 0.69 | CYP1A2 (0.46) | CYP1A2ERBB2FYNMAOAACHE | |
| SCHEMBL5702406 | 0.69 | CYP1A2 (0.42) | CYP1A2ERBB2FYNMAOAACHE | |
| SCHEMBL290497 | 0.69 | ALDH1A1 (0.42) | CYP1A2ERBB2FYNMAOAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6376655-B1 | APPLYING EXTERNAL STIMULATION; OPTICAL ANISOTROPY | RISO NATIONAL LABORATORY (DK) | 2002-04-23 | — | — | US | claimed |
| EP-0400038-A1 | WATER-DISSIPATABLE POLYESTER AND POLYESTER-AMIDES CONTAINING COPOLYMERIZED COLORANTS | EASTMAN CHEMICAL COMPANY (US) | 1990-12-05 | — | — | EP | claimed |
| WO-1989007118-A1 | WATER-DISSIPATABLE POLYESTER AND POLYESTER-AMIDES CONTAINING COPOLYMERIZED COLORANTS | EASTMAN KODAK COMPANY (US) | 1989-08-10 | — | — | WO | claimed |
| CN-110520459-A | Process for preparing poly (trimethylene furandicarboxylate) using zinc catalyst | DUPONT IND BIOSCIENCES USA LLC | 2019-11-29 | — | — | CN | disclosed |
| CN-109689085-A | COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION | 阿塞勒隆制药公司 | 2019-04-26 | — | — | CN | disclosed |
| WO-2015054333-A1 | METHODS OF TREATING CANCER USING COMPOSITIONS COMPRISING PERILLYL ALCOHOL DERIVATIVE | Neonc Technologies, Inc. (US) | 2015-04-16 | — | — | WO | disclosed |
| EP-1507778-B1 | ANTI-TUMOUR POLYCYCLIC CARBOXAMIDES | UNIV TROBE (AU) | 2012-02-22 | — | — | EP | disclosed |
| EP-2155908-A1 | GERMLINE POLYMORPHISMS IN THE ANGIOGENIC PATHWAY PREDICT TUMOR RECURRENCE IN CANCER THERAPY | University Of Southern California (US) | 2010-02-24 | — | — | EP | disclosed |
| EP-2109686-A2 | GENETIC MARKERS FOR PREDICTING RESPONSIVENESS TO COMBINATION THERAPY | University Of Southern California (US) | 2009-10-21 | — | — | EP | disclosed |
| US-20090156630-A1 | ANTI-TUMOUR POLYCYCLIC CARBOXAMIDES | BAGULEY BRUCE CHARLES | 2009-06-18 | — | — | US | disclosed |
| US-7504507-B2 | Anti-tumour polycyclic carboxamides | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-03-17 | — | — | US | disclosed |
| WO-2008144512-A1 | GERMLINE POLYMORPHISMS IN THE ANGIOGENIC PATHWAY PREDICT TUMOR RECURRENCE IN CANCER THERAPY | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008088854-A2 | GENETIC MARKERS FOR PREDICTING RESPONSIVENESS TO COMBINATION THERAPY | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20050245561-A1 | Anti-tumour polycyclic carboxamides | AUCKLAND UNISERVICES LIMITED (NZ) | 2005-11-03 | — | — | US | disclosed |
| US-6526213-B1 | Colorless white light transmission | FIBERSTARS INCORPORATED | 2003-02-25 | — | — | US | disclosed |
| US-6376655-B1 | APPLYING EXTERNAL STIMULATION; OPTICAL ANISOTROPY | RISO NATIONAL LABORATORY (DK) | 2002-04-23 | — | — | US | disclosed |
| US-5104913-A | Copolymer of thermoplastic polyester and colorant; controlled particle size | EASTMAN KODAK COMPANY (US) | 1992-04-14 | — | — | US | disclosed |
| US-5043376-A | Blend of water insoluble polymeric colorant and surfactant | EASTMAN KODAK COMPANY (US) | 1991-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156630-A1 | ANTI-TUMOUR POLYCYCLIC CARBOXAMIDES | MKI67, MCL1, CCNI | CYP1A2 1244/4885ERBB2 912/4885FYN 4245/4885 |
| US-20050245561-A1 | Anti-tumour polycyclic carboxamides | MKI67, MCL1, CCNI | CYP1A2 1358/4885ERBB2 792/4885FYN 4021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.